VEGFA and neoplasm: Based on the association of the immune-activated, highly immunogenic CMS1 tumor subtype with right-sided tumor location [39] on the one hand, and the strong association of favorable circulating immune signature (low Tregs, high CD8+ T cells, high CD8:Treg ratio) and favorable clinical outcome in primary right-sided mCRC on the other, we propose that right-sided mCRC patients with favorable circulating immune signature overlap with a subgroup of patients with immune-activated tumors that clearly benefit from immunomodulatory anti-VEGF-based therapy.